Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 104

1.

Bleeding risk of patients with acute venous thromboembolism taking nonsteroidal anti-inflammatory drugs or aspirin.

Davidson BL, Verheijen S, Lensing AW, Gebel M, Brighton TA, Lyons RM, Rehm J, Prins MH.

JAMA Intern Med. 2014 Jun;174(6):947-53. doi: 10.1001/jamainternmed.2014.946.

PMID:
24733305
[PubMed - in process]
2.

Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis.

van Walraven C, Hart RG, Singer DE, Laupacis A, Connolly S, Petersen P, Koudstaal PJ, Chang Y, Hellemons B.

JAMA. 2002 Nov 20;288(19):2441-8.

PMID:
12435257
[PubMed - indexed for MEDLINE]
3.

Cost-effectiveness of rivaroxaban compared with enoxaparin plus a vitamin K antagonist for the treatment of venous thromboembolism.

Lefebvre P, Coleman CI, Bookhart BK, Wang ST, Mody SH, Tran KN, Zhuo DY, Huynh L, Nutescu EA.

J Med Econ. 2014 Jan;17(1):52-64. doi: 10.3111/13696998.2013.858634. Epub 2013 Nov 14.

PMID:
24156243
[PubMed - in process]
4.

Dabigatran etexilate and concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid in patients undergoing total hip and total knee arthroplasty: no increased risk of bleeding.

Friedman RJ, Kurth A, Clemens A, Noack H, Eriksson BI, Caprini JA.

Thromb Haemost. 2012 Jul;108(1):183-90. doi: 10.1160/TH11-08-0589. Epub 2012 May 3.

PMID:
22552763
[PubMed - indexed for MEDLINE]
5.

Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study.

Lamberts M, Gislason GH, Lip GY, Lassen JF, Olesen JB, Mikkelsen AP, Sørensen R, Køber L, Torp-Pedersen C, Hansen ML.

Circulation. 2014 Apr 15;129(15):1577-85. doi: 10.1161/CIRCULATIONAHA.113.004834. Epub 2014 Jan 27.

PMID:
24470482
[PubMed - indexed for MEDLINE]
6.

Stroke Prevention in Atrial Fibrillation [Internet].

Lopes RD, Crowley MJ, Shah BR, Melloni C, Wood KA, Chatterjee R, Povsic TJ, Dupre ME, Kong DF, de Barros e Silva PGM, dos Santos MHH, Armaganijan LV, Katz M, Kosinski A, McBroom AJ, Chobot MM, Gray R, Sanders GD.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 Aug.

PMID:
24049843
[PubMed]
Books & Documents
7.

Oral rivaroxaban for symptomatic venous thromboembolism.

EINSTEIN Investigators, Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovella F, Schellong S.

N Engl J Med. 2010 Dec 23;363(26):2499-510. doi: 10.1056/NEJMoa1007903. Epub 2010 Dec 3.

PMID:
21128814
[PubMed - indexed for MEDLINE]
Free Article
8.

Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial.

Mahaffey KW, Wojdyla D, Hankey GJ, White HD, Nessel CC, Piccini JP, Patel MR, Berkowitz SD, Becker RC, Halperin JL, Singer DE, Califf RM, Fox KA, Breithardt G, Hacke W.

Ann Intern Med. 2013 Jun 18;158(12):861-8. doi: 10.7326/0003-4819-158-12-201306180-00003.

PMID:
23778903
[PubMed - indexed for MEDLINE]
9.

Concomitant use of medication with antiplatelet effects in patients receiving either rivaroxaban or enoxaparin after total hip or knee arthroplasty.

Eriksson BI, Rosencher N, Friedman RJ, Homering M, Dahl OE.

Thromb Res. 2012 Aug;130(2):147-51. doi: 10.1016/j.thromres.2011.12.005. Epub 2012 Jan 5.

PMID:
22225858
[PubMed - indexed for MEDLINE]
10.

Warfarin, kidney dysfunction, and outcomes following acute myocardial infarction in patients with atrial fibrillation.

Carrero JJ, Evans M, Szummer K, Spaak J, Lindhagen L, Edfors R, Stenvinkel P, Jacobson SH, Jernberg T.

JAMA. 2014 Mar 5;311(9):919-28. doi: 10.1001/jama.2014.1334.

PMID:
24595776
[PubMed - indexed for MEDLINE]
11.

Managing pulmonary embolism from presentation to extended treatment.

Cohen AT, Dobromirski M, Gurwith MM.

Thromb Res. 2014 Feb;133(2):139-48. doi: 10.1016/j.thromres.2013.09.040. Epub 2013 Oct 14.

PMID:
24182642
[PubMed - in process]
12.

Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis.

Linkins LA, Choi PT, Douketis JD.

Ann Intern Med. 2003 Dec 2;139(11):893-900.

PMID:
14644891
[PubMed - indexed for MEDLINE]
13.

Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.

EINSTEIN–PE Investigators, Büller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, Chlumsky J, Verhamme P, Wells P, Agnelli G, Cohen A, Berkowitz SD, Bounameaux H, Davidson BL, Misselwitz F, Gallus AS, Raskob GE, Schellong S, Segers A.

N Engl J Med. 2012 Apr 5;366(14):1287-97. doi: 10.1056/NEJMoa1113572. Epub 2012 Mar 26.

PMID:
22449293
[PubMed - indexed for MEDLINE]
Free Article
14.

Rivaroxaban: a review of its use in the treatment of deep vein thrombosis or pulmonary embolism and the prevention of recurrent venous thromboembolism.

Burness CB, Perry CM.

Drugs. 2014 Feb;74(2):243-62. doi: 10.1007/s40265-013-0174-4.

PMID:
24430916
[PubMed - in process]
15.

Aspirin for preventing the recurrence of venous thromboembolism.

Becattini C, Agnelli G, Schenone A, Eichinger S, Bucherini E, Silingardi M, Bianchi M, Moia M, Ageno W, Vandelli MR, Grandone E, Prandoni P; WARFASA Investigators.

N Engl J Med. 2012 May 24;366(21):1959-67. doi: 10.1056/NEJMoa1114238. Erratum in: N Engl J Med. 2012 Oct 18;367(16):1573.

PMID:
22621626
[PubMed - indexed for MEDLINE]
Free Article
16.

Benefit-risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty.

Levitan B, Yuan Z, Turpie AG, Friedman RJ, Homering M, Berlin JA, Berkowitz SD, Weinstein RB, DiBattiste PM.

Vasc Health Risk Manag. 2014 Mar 26;10:157-67. doi: 10.2147/VHRM.S54714. eCollection 2014.

PMID:
24707185
[PubMed - in process]
Free PMC Article
17.

Antiplatelet and anticoagulant drugs for prevention of restenosis/reocclusion following peripheral endovascular treatment.

Robertson L, Ghouri MA, Kovacs F.

Cochrane Database Syst Rev. 2012 Aug 15;8:CD002071. doi: 10.1002/14651858.CD002071.pub3. Review.

PMID:
22895926
[PubMed - indexed for MEDLINE]
18.

Low-dose aspirin for preventing recurrent venous thromboembolism.

Brighton TA, Eikelboom JW, Mann K, Mister R, Gallus A, Ockelford P, Gibbs H, Hague W, Xavier D, Diaz R, Kirby A, Simes J; ASPIRE Investigators.

N Engl J Med. 2012 Nov 22;367(21):1979-87. doi: 10.1056/NEJMoa1210384. Epub 2012 Nov 4.

PMID:
23121403
[PubMed - indexed for MEDLINE]
Free Article
19.

The risk of bleeding with duloxetine treatment in patients who use nonsteroidal anti-inflammatory drugs (NSAIDs): analysis of placebo-controlled trials and post-marketing adverse event reports.

Perahia DG, Bangs ME, Zhang Q, Cheng Y, Ahl J, Frakes EP, Adams MJ, Martinez JM.

Drug Healthc Patient Saf. 2013 Nov 25;5:211-9. doi: 10.2147/DHPS.S45445. eCollection 2013.

PMID:
24348072
[PubMed]
Free PMC Article
20.

Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.

Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, Kabbinavar F, Bergsland E, Ngai J, Holmgren E, Wang J, Hurwitz H.

J Natl Cancer Inst. 2007 Aug 15;99(16):1232-9. Epub 2007 Aug 8. Erratum in: J Natl Cancer Inst. 2008 Jan 16;100(2):156. J Natl Cancer Inst. 2008 May 7;100(9):685.

PMID:
17686822
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk